14 assets in Lung Neuroendocrine Neoplasm

Therapeutic assets addressing Lung Neuroendocrine Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Lung Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P3	B (60)
Everolimus Lung Neuroendocrine Neoplasm	AC Camargo Cancer Center	P2	CCC (53)
Foslinanib Lung Neuroendocrine Neoplasm	TaiRx, Inc.	P2	CCC (53)
Ifa Lung Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Ipilimumab Lung Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Lung Neuroendocrine Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Sargramostim Lung Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Surufatinib Lung Neuroendocrine Neoplasm	Hutchmed	P2	CCC (53)
Survaxm Lung Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
177lu-dtpa-sc16.56 Lung Neuroendocrine Neoplasm	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Berzosertib Lung Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
212-lead pentixather Lung Neuroendocrine Neoplasm	Yusuf Menda	Early P1	C (39)
[212pb] vmt-α-net Lung Neuroendocrine Neoplasm	David Bushnell	Early P1	C (39)
Nab-Sirolimus Lung Neuroendocrine Neoplasm	Aadi Bioscience, Inc.	P2	NR ()